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1. INTRODUCTION 
The present “Report on the Development, Validation and Legal Acceptance of Alternative 
Methods to Animal Experiments in the Field of Cosmetics” is the seventh report presented by 
the Commission. It reflects the state of play in terms of the number and type of experiments 
on animals relating to cosmetic products in 2005 and 2006, the current status of alternative 
replacement methods, and the acceptance and recognition of alternative methods at 
international level. The report is produced in order to comply with Article 9 of Council 
Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States 
relating to cosmetic products (hereinafter “Cosmetics Directive”), as amended by the 
European Parliament and Council Directive 2003/15/EC of 27 February 2003. It is the third 
report on the basis of the 7th Amendment to the Cosmetics Directive and following the 
inclusion of the Protocol on the Welfare of Animals in the Treaty of Amsterdam in 1999. 
2. NUMBER AND TYPE OF EXPERIMENTS RELATING TO COSMETIC PRODUCTS 
CARRIED OUT ON ANIMALS 
2.1. Legal Background 
According to Article 9 (a) of the Cosmetics Directive, every year the Commission shall 
present a report to the European Parliament and the Council on progress made in the 
development, validation and legal acceptance of alternative methods. The report shall contain 
precise data on the number and type of experiments relating to cosmetic products carried 
out on animals. The Member States shall be obliged to collect that information in addition to 
collecting statistics as laid down by Council Directive 86/609/EEC of 24 November 1986 on 
the approximation of laws, regulations and administrative provisions of the Member States 
regarding the protection of animals used for experimental and other scientific purposes 
(Experimental Animals Directive). The Experimental Animals Directive includes 
requirements to report at regular intervals not exceeding three years on the number and 
kinds of animals used in experiments. 
The information to be provided under the Cosmetics Directive should enable the European 
Commission and the Member States to gain a complete picture of the situation in the field of 
animal testing in relation to cosmetic products. This information will be useful in order to 
apply the relevant provisions of the Cosmetics Directive. 
The ban on the testing of finished cosmetic products has been in force since 11 September 
2004, whereas the ban on testing ingredients or combination of ingredients will be 
implemented gradually as alternative methods are validated and adopted; however there will 
be a maximum cut-off date of six years after the entry into force of the Directive, i.e. 11 
March 2009, irrespective of the availability of alternative non-animal tests. The marketing ban 
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will apply step by step as soon as alternative methods are validated and adopted in EU 
legislation, with due regard to the OECD validation process. This marketing ban will be 
introduced at the latest six years after entry into force of the Directive, i.e. by 11 March 2009, 
for all human health effects with the exception of repeated-dose toxicity, reproductive toxicity 
and toxicokinetics. For these specific health effects, a deadline of 10 years after entry into 
force of the Directive is laid down, i.e. 11 March 2013, regardless of the availability of 
alternative non-animal tests. 
2.2. Animal Testing Data1 
For the present report, 26 Member States supplied information on animal tests carried out for 
the safety of cosmetic products in 2005 and 2006. Despite several requests, Portugal did not 
transmit any information for this report under Article 9 (a) of the Cosmetics Directive. As 
mentioned in a reminder letter addressed to Member States, the Commission will consider 
opening infringement procedure. 
According to the information submitted, cosmetic ingredients have only been tested on 
animals in the territories of France2 and Romania. These Member States provided detailed 
information, including the testing period, the toxicological test endpoint, species of animals 
used for experiments and number of animals used for testing (Table 2).  
In total, about 2 276 animals in 2005 and about 1329 animals in 2006 were used in tests 
carried out in relation to the safety of cosmetic ingredients (Table 1). The other 24 Member 
States reported that they did not perform such animal tests in their territory in 2005/2006 or 
that they cannot provide the information for the reasons explained below (see 3.b). 
Number of animals used in Member States (2005/2006) – Table 1 
 NUMBER OF ANIMALS USED ANIMALS USED 
 2005 2006  
ROMANIA 40 40 Rats 
FRANCE 2236 1289 Mice, rats, guinea pigs, rabbits 
Total 2276 1329  
 
                                                 
1 See reservations on the accuracy of data in paragraph 3 “Evaluation of submitted data”  
2 There are four laboratories which perform animal testing in France for cosmetic ingredients or 
combination of ingredients. Research protocols are done for French clients and client from one another 
Member State. 
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Number of Animals Used in Relation to Toxicological Endpoints (2005/2006) – Table 2 
TYPES OF TESTS / COUNTRIES ROMANIA FRANCE 
 2005 2006 2005 2006 
Skin irritation   165 248 
Eye irritation   205 250 
Skin sensitivity 40 40 1473 455 
Photosensitivity   132 113 
Oral toxicity   261 223 
The total number of animals used for testing the safety of cosmetics showed a significant fall 
compared to the last report (2003: 1618, 2004: 8998). Indeed, the figures for 2006 are below 
those of 2003, even though twelve3new Member States joined the EU in that period. 
As mentioned in the last report, the reported number of animals used for the testing of 
cosmetics or toiletries is still relatively small compared to the total number of animals used 
for experimental and other scientific purposes. The Fifth Report on the Statistics on the 
Number of Animals used for Experimental and other Scientific Purposes in the Member 
States of the European Union4 mentioned that 8% of the total number of animals used for 
experimental purposes are used for toxicological and other safety evaluations, of which 
cosmetics represent 0.5%. 
2.3. Evaluation of submitted data 
In August 2007, the Commission asked Member States to send accurate data on the number 
and type of experiments relating to cosmetic products carried out on animals in 2005 and 
2006 in accordance with Article 9 (a) of the Cosmetics Directive. The Commission specified 
that this information should also explain precisely what the figures represent and the way in 
which they were collated. 
Furthermore, the Commission annexed to this request the guidelines announced in the 2005 
Report in order to facilitate accurate generation and collation of animal testing data relating to 
cosmetic products. 
2.3.1. Main explanations given by Member States: 
The majority of Member States replied that no animal testing in relation to cosmetic products 
was performed in 2005 and 2006 in their territory. The main explanations they gave to 
substantiate their replies were the following: 
– National legislation prohibits the carrying out of animal experiments in order to test 
and develop cosmetic products and their ingredients. Interestingly, sometimes some 
                                                 
3 Bulgaria and Romania provided data, even if they joined afterwards. 
4 5.11.2007, COM(2007) 675 final 
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Member States specify that testing for cosmetic purposes is prohibited within 
multiple use tests. 
– National legislation stipulates that animal testing must be authorised in order to be 
lawfully performed, and therefore:  
– No authorisation was given to laboratories to test and develop cosmetic 
products and their ingredients; 
– There are no approved establishments for animal experiments relating to 
cosmetic products. 
– The following do not exist on national territory  
– testing facilities for animal testing related to human health; or 
– laboratories complying with the requirements of good laboratory practice 
where non-clinical studies of the health and environmental safety of substances 
could be carried out. 
– The authorities responsible for checking cosmetic products and carrying out market 
surveillance do not conduct or commission animal experiments for the purposes of 
such checks. 
– A letter and a questionnaire were sent to representatives of cosmetic product 
manufacturers. 
– Competent authorities checked the product information file which, according to 
Article 7a, paragraph 1(h) of the Cosmetics Directive, must contain “data on any 
animal testing performed by the manufacturer, his agents or suppliers, relating to the 
development or safety evaluation of the product or its ingredients, including any 
animal testing performed to meet the legislative or regulatory requirements of non-
member countries”. They found nothing to suggest that chemical substances used as 
ingredients in cosmetics had been tested on animals. 
2.3.2. Details of difficulties encountered by Member States 
Some Member States elaborate on their replies by mentioning the difficulties they had in 
collecting the information. 
As mentioned in the previous report, chemicals are rarely tested on animals solely for their 
use as ingredients in cosmetics, and the majority of animal tests are conducted for multiple 
uses by manufacturers of chemical substances (industry assumes that approximately 80-90% 
of cosmetic ingredients are tested for multiple uses). Therefore, some Member States 
acknowledged that it is difficult to determine which results of which research may 
subsequently be referred to by the cosmetic industry. 
Sweden explained that it considers itself unable to provide the requested information, as in its 
view it does not have the legal basis to make such a request to companies. Indeed, the 
information provided according to Article 7a, paragraph 1(h) is only required to be readily 
accessible to the competent authorities of the Member State. 
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2.3.3. Initiatives taken by Member States for the collection of data 
In view of the situation and the efforts requested of the Member States by the Commission to 
deliver the appropriate information, some Member States did provide information about the 
initiatives considered: 
– In order to ensure greater transparency in the data received, the toxicology laboratory 
that normally carries out the most tests for third parties has initiated an internal 
procedure under which clients are required to declare that the substances sent for 
testing will not be used as ingredients in cosmetic products. 
– The supplier or manufacturer or the person responsible for placing the cosmetic 
product on the market shall inform the National Chemicals Bureau about the types 
and number of tests they have conducted on animals in connection with the purpose 
of ensuring their suitability and compliance with the cosmetic legislation. 
– In order to simplify data collection, the possibility of making it obligatory for 
manufacturers to submit information on tests carried out on animals once a year is 
being examined. 
2.3.4. Conclusion 
The Commission continues to be concerned about the accuracy of the figures being reported, 
and this concern is shared by Member States.  
The main issue relates to multi-use substances. Interestingly, some Member States, when 
mentioning that no animal testing has been performed for cosmetic products, reported that no 
toxicological tests were carried out for multiple or uncertain purposes where it could be 
considered that the substance might be used as an ingredient in cosmetic products. 
The Commission considers that the best available source for information at national level is 
the information held according to Article 7a (1) (h). It is also the most suitable way to enforce 
the marketing ban laid down in Article 4a of the Cosmetics Directive. The implementation of 
REACH5 would allow passing this information to the downstream user of the ingredient. 
Within this context, the Commission will consider how further improve the availability of 
relevant information.  
                                                 
5 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 
concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), 
establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council 
Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council 
Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 
2000/21/EC, OJ L 396 of 30.06.2006 p. 1. 
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3. PROGRESS IN THE DEVELOPMENT, VALIDATION AND LEGAL ACCEPTANCE OF 
ALTERNATIVE METHODS 
3.1. Legally Accepted Replacement Methods 
3.1.1. Under Annex IX of the Cosmetics Directive 
Annex IX of the Cosmetics Directive “lists the alternative methods validated by the European 
Centre on Validation of Alternative Methods (ECVAM) of the Joint Research Centre 
available to meet the requirements of this Directive and which are not listed in Annex V to 
Council Directive 67/548/EEC on the approximation of laws, regulations and administrative 
provisions relating to the classification, packaging and labelling of dangerous substances”. 
The purpose of Annex IX of the Cosmetics Directive is to supplement Annex V of Council 
Directive 67/548/EEC. Annex IX was created in order to ensure, without delay, the regulatory 
acceptance of alternative methods that would not be applicable to the whole chemical sector, 
but only to the cosmetic sector. Indeed, recital 5 of Directive 2003/15/EC of the European 
Parliament and of the Council provides the following background: “Currently [in 2003], only 
alternative methods which are scientifically validated by the European Centre for the 
Validation of Alternative Methods (ECVAM) or the Organisation for Economic Cooperation 
and Development (OECD) and applicable to the whole chemical sector are systematically 
adopted at Community level. However, the safety of cosmetic products and their ingredients 
may be ensured through the use of alternative methods which are not necessarily applicable to 
all uses of chemical ingredients. Therefore, the use of such methods by the whole cosmetic 
industry should be promoted and their adoption at Community level ensured, when such 
methods offer an equivalent level of protection to consumers”. 
Considering that ECVAM did not validate alternative methods to animal testing that would 
not be applicable to the whole chemical sector, Annex IX was not amended in 2007 and is 
still empty. 
3.1.2. Under Annex V of Council Directive 67/548/EEC 
The adoption of the 30th adaptation to technical progress of Council Directive 67/548/EEC, 
amending in particular Annex V, has been delayed due to the procedure under the Technical 
Barriers to Trade agreement. 
This draft Directive provides for an update of the following methods which were already 
listed:  
– B. 40. In vitro skin corrosion: transcutaneous electrical resistance test (TER), 
equivalent to the OECD TG 430 (2004); 
– B. 40 Bis. In vitro skin corrosion: human skin model test, equivalent to the OECD 
TG 431 (2004); 
– B. 41. In Vitro 3T3 NRU phototoxicity test, equivalent to OECD TG 432 (2004); 
And for the introduction of the following method concerning skin absorption:  
– B. 45. skin absorption (skin penetration): in vitro Method, equivalent to the OECD 
TG 428 (2004). 
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3.1.3. Under the Commission Regulation on the adoption of testing methods under 
Regulation 1907/2006 (the “REACH” Regulation) 
Directive 2006/121/EC6 of the European Parliament and of the Council provides for the 
deletion of Annex V of Council Directive 67/548/EEC as from 1 June 2008. The Commission 
has therefore adopted an implementation Regulation under REACH, which brings together, in 
one Regulation, all the test methods contained in Annex V to Directive 67/548/EEC7.  
3.2. Progress in Development and Validation of Alternative Approaches 
3.2.1. ECVAM Technical Report 
The European Centre for the Validation of Alternative Methods (ECVAM) of the EC’s Joint 
Research Centre (JRC) prepared a “Cosmetics Technical Report” which is published in annex 
to this report. Although the figures in this report cover the period 2005-2006, the technical 
report also covers the year 2007. It assesses the possibility of fully replacing animal tests 
before the cut-off dates set out in Article 4a of the Cosmetics Directive. 
3.2.1.1. For the end points falling under the 2009 deadline 
For skin corrosion, acute phototoxicity and skin penetration, as mentioned in the 2005 report, 
accepted replacement assays already exist. 
For in vitro skin irritation testing, ECVAM declared as scientifically validated an assay based 
on reonstituted human epidermis (EPISKIN TM) in April 2007. This method is currently 
undergoing regulatory acceptance in the EU. 
For mutagenicity, in vitro methods have already been incorporated in legislation8. However, 
under the current test strategy for genotoxicity, positive results obtained from these methods 
require confirmation by animal testing due to the fact that they produce a high number of false 
positives. Although the primary screening of substances is based on in vitro methods, the 
deadline of 2009 might still pose a problem. Indeed, owing to the existence of false positives, 
which cannot be reduced in the absence of alternative methods to animal testing for the 
confirmation of results, the number of active cosmetic ingredients would be reduced, for 
reasons not linked to their safety. 
For eye irritation, the 2009 deadlines for full replacement are unlikely to be met. The 
validated tests and tests strategies available would allow only for the partial replacement of 
the animal test. Therefore, research is ongoing in order to allow such a replacement in future. 
For acute toxicity, because the results of the DG RTD funded A-cute-Tox EU project will not 
be available until 2009 results will not become available until 2010 onwards. 
                                                 
6 Directive 2006/121/EC of the European Parliament and of the Council of 18 December 2006 amending 
Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions 
relating to the classification, packaging and labelling of dangerous substances in order to adapt it to 
Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction 
of Chemicals (REACH) and establishing a European Chemicals Agency, OJ L 396 of 30.12.2006. 
7 OJ L 142 of 31.05.2008 
8 In Annex VIII of Regulation 1907/2006 REACH  
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3.2.1.2. For the endpoints falling under the 2013 deadline 
As already mentioned in the 2005 report, there is unfortunately no indication that the deadline 
can be met for the complex endpoints, such as chronic toxicity, reproductive toxicity and 
toxicokinetics, although several activities are ongoing. The only area for optimism would 
appear to be skin sensitisation, depending on the results of the integrated project Sens-it-iv. 
3.2.2. SCCP statements 
In 2007, the Scientific Committee on Consumer Products (SCCP), who is responsible for the 
evaluation of the substance used in cosmetic products, delivered, on its own initiative, two 
statements regarding the availability of alternative methods.  
In its memorandum of June 2007 on the Actual Status of Alternative Methods on the Use of 
Experimental Animals in the Safety Assessment of Cosmetic Ingredients in the European 
Union9, the SCCP expressed its concerns regarding the availability of alternative methods to 
animal testing to conduct safety assessment, opposed to hazard identification. 
In its memorandum of December 200710on the in vitro test EPISKIN™ for skin irritation 
testing, the SCCP underlined the possible limited applicability of this method regarding 
colouring agents and hair dyes. This aspect was mentioned by ECVAM when transmitting 
this method for regulatory acceptance under Annex V of Council Directive 67/548/EEC. 
3.2.3. RTD activities  
Developing robust and effective, novel, alternative methods has been a priority under the 
Framework Research Programmes of the European Union for more than 20 years. The first 
calls for proposals under the 7th RTD Framework Programme resulted in the selection of five 
proposals on the Theme “Health” (two large–scale integrating projects, two focused research 
projects, and one specific support action, expected EU contribution: €30 million). The areas 
addressed by the Theme “Health” include: profiling the toxicity of new drugs and of 
nanoparticles in medical diagnostics without animal tests, QSAR models in the field of 
predictive toxicology and bottlenecks in the 3R approach in pharmaceutical development. 
Two proposals have been selected for funding in the Theme “Environment” (2 focused 
research projects in the field of in-silico methods; expected EU contributions: €5 million). 
Even though the projects are tailor-made for specific areas, it is expected that their results will 
be widely transferable to other areas relevant for the implementation of the 3R concept. 
3.2.4. COLIPA (The European Cosmetic Toiletry and Perfumery Association) 
It has a research programme on Alternative Approaches to Animal Testing (AAT) to support 
the development, validation and acceptance of alternative approaches in order to replace 
animal use.  
For eye irritation, COLIPA submitted to ECVAM in beginning of 2008 results from the 
optimization of the two most advanced Human Reconstructucted Tissue models11. 
                                                 
9 SCCP/1111/07; http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_s_06.pdf 
10 SCCP/1145/07; http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_s_07.pdf 
11 SkinEthic Human Corneal Epithelium (HCE) model and the MatTek Epiocular model 
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For genotoxicity and mutagenicity, COLIPA is working to develop approached to reduce the 
“false positive” rate of in vitro mammalian cell genotoxicity assays and to develop genotoxic 
assays in 3D human skin models. 
For skin allergy, COLIPA is aiming to propose three methods for validation to ECVAM in 
200812. 
3.2.5. Others 
The ongoing activities mentioned in the 2005 report, such as the European Partnership for 
Alternative Approaches to Animal Testing (EPAA)13 the Community Action Plan on the 
Protection and Welfare of Animals14 and the revision of Directive 86/609/EEC on the 
protection of animals used in experiments15, were continued. 
4. ACCEPTANCE AND RECOGNITION OF ALTERNATIVE METHODS AT INTERNATIONAL 
LEVEL 
The Commission has put the issues of validation and regulatory acceptance of alternative 
methods at the top of its agenda of sectoral regulatory dialogues at both multilateral and 
bilateral level. 
4.1. Multilateral level 
The Commission met with its counterparts from the United States, Japan and Canada at the 
"International Cooperation on Cosmetic Regulation" (“ICCR”) meeting from 26 to 28 
September 2007. One focal point of this meeting was exploring hurdles in the international 
regulatory acceptance of alternative testing methods. It was concluded that it is therefore 
crucial to ensure that, at the validation stage, the assessments within different jurisdictions do 
not differ. 
An agreement at the “validation stage” would be a great help in ensuring harmonised 
regulatory acceptance, thus facilitating trade and enhancing animal welfare. 
In order to avoid different recommendations after validation and peer review of alternative 
methods/approaches, the Commission is working towards establishing an international 
collaboration on validation/peer review processes in various regions. Discussions have started 
between the EU and US in the framework of the Transatlantic Economic Council (see below). 
In addition to these efforts, the Commission is cooperating with the OECD by, regularly 
taking part in meetings and working groups, such as the OECD Working Group of the 
National Coordinators of the Test Guidelines Programme, the Endocrine Disrupters Testing 
and Assessment Task force and its subgroups, that deal with non-animal tests (e.g. Validation 
Management Group - Non-Animal), and other ad-hoc expert groups dealing with various 
alternative methods. 
                                                 
12 Human Cell Line Activation Test (h-CLAT), U937/CD86 and a pepttide-binding assay. 
13 For further information see http://www.ec.europa.eu/enterprise/epaa/index_en.htm 
14 COM (2006) 13 final, 23.1.2006 
15 For further information see http://ec.europa.eu/environment/chemicals/lab_animals/revision_en.htm 
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4.2. Bilateral level 
Questions of validation and regulatory acceptance of alternative methods are also at the core 
of the various bilateral regulatory dialogues with the main trading partners. In particular: 
4.2.1. U.S. 
Making progress on issues of validation and regulatory acceptance of alternative methods is 
one of the key deliverables agreed under the Transatlantic Economic Framework, and this 
work is closely monitored by the Transatlantic Economic Council (TEC). 
The issue was discussed at the meeting with the TEC on 9 November 2007 in Washington 
between Vice-President Günter Verheugen and the then Director of National Economic 
Advisors/Special Assistant to the US President, Al Hubbard. 
The EU and the United States agreed that the approach chosen at the multilateral level (see 
above) is crucial and are working towards the swift establishment of a joint validation/peer 
review process taking into account the specific demands of different jurisdictions as far as 
possible. 
ECVAM and IICVAM are collaborating on several validation studies and ICCVAM has an 
observer status on the EVCAM Scientific Advisory Committee (ESAC). 
ICCVAM also participated in the annual conferences of EPAA in 2006 and 2007. 
4.2.2. Japan 
In Japan, animal testing of cosmetic products and their ingredients is not obligatory per se. 
However, animal tests are conducted in the framework of the regulation of cosmetics 
ingredients and “quasi-drugs”, some of which are considered as cosmetic products in the 
EU.16 
Issues of animal testing have been repeatedly raised, particularly in the framework of the 
regulatory reform dialogues in 2006 and 2007. In 2006, Japan stressed its commitment to 
implement OECD testing guidelines. In 2007, Japan indicated a clear interest in participating 
in the setting-up of an international validation process as discussed at the ICCR (see above). 
Moreover, activities in the field of validation are also ongoing under the co-ordination of 
JaCVAM (Japanese Centre for the Validation of Alternative Methods). ECVAM is an official 
member in the validation management teams whereas observers from JaCVM are regulatory 
invited to meetings of the ECVAM Scientific Advisory Board (ESAC). 
4.2.3. China 
The regulatory system in China is particularly challenging, as animal testing on the finished 
cosmetic product is obligatory in order to have market access. These tests are often carried out 
by the competent authorities under a marketing authorisation. 
The issue has been discussed in numerous fora, and in particular at 
                                                 
16 For example, deodorants, hair dyes and certain oral care products. 
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– the EU-China (AQSIQ) working group on cosmetic products which met on 15 
September 2006 in Brussels and on 24 October 2007 in Beijing. At the invitation of 
the Commission, AQSIQ also participated at the second annual conference of EPPA 
on 18 December 2006. 
– the meeting of the Commission with the Chinese SFDA on 4 July 2007 in Brussels; 
Moreover, questions about animal testing were raised in several comments by the EU on 
notifications under the TBT agreement.17 
5. CONCLUSION 
It can be noted that Member States have improved their internal structure in order to provide 
for accurate animal testing data and effective monitoring of the application of the testing and 
marketing bans, as it was encouraged in the guidelines annexed to the request to Member 
States for accurate data18.  
There are currently four alternative in vitro methods in relation to three toxicological 
endpoints (skin corrosion, acute phototoxicity and skin penetration) listed in Annex V of 
Directive 67/548/EEC and one method for the mutagenicity testing listed under REACH19. 
These alternative test methods are currently the only legally accepted tests at Community 
level aimed at fully replacing animal tests for toxicological endpoints in the area of chemicals 
and cosmetic products. A method concerning skin irritation is likely to be soon accepted for 
regulatory purposes. For eye irritation and acute toxicity, the situation is uncertain and the 
Commission will focus its efforts on these human health effects in view of the 2009 deadline. 
For the 2013 deadline, the situation is much more critical. The replacement of animal test 
methods by alternative methods in relation to complex toxicological endpoints remains 
scientifically difficult, despite the additional efforts launched at various levels. 
                                                 
17 Cf. in particular notification G/TBT/N/CHN/209 - Hygienic specifications for cosmetics. 
18 See paragraph 2.3. 
19 Listed under Annex VIII of Regulation 1907/2006. 
